The MHRA position, summarised by Lynda Scammell (head of borderline products at the MHRA) and reported in The Guardian on 4 April 2026, is that products which are sold for human use or which carry medicinal claims fall inside the Human Medicines Regulations 2012, and that the MHRA is investigating UK clinics making such claims about unregulated peptide products
PlexusDx protocols overlap tirzepatide initiation with gradual semaglutide tapering over 12 weeks, maintaining continuous receptor activation and preventing metabolic whiplash
Understanding these mechanisms can help you and your healthcare provider manage this side effect more effectively
Which are the intracellular targets of melatonin
7 GI side effects are not only major contributors to stopping GLP-RAs, but are more likely to be reported as such by patients than by their physicians
This log becomes invaluable when evaluating results, troubleshooting issues, or planning future protocols